Connect with us

Hi, what are you looking for?


Southeast Asia’s virus hotspot bets on early vaccine rollout


INDONESIA, the world’s fourth most-populous nation that’s battling Southeast Asia’s worst coronavirus outbreak, is gearing for a massive vaccination program that the government wants to start as soon as next month.

The government plans to kick off with an initial 3 million doses in December, prioritizing health workers, police, military and public servants, according to Budi Gunadi Sadikin, who leads the national economic recovery task force. The government expects another 13 million to be inoculated in the first quarter of 2021, with a majority of Indonesians receiving their jabs later in the year.

“I hope the vaccine will come by end of this month, we are trying,” said President Joko Widodo in a Wednesday briefing after supervising a vaccination simulation. “But if it can’t, it will come next month whether in raw material or as a finished good.”

Indonesia is banking on a vaccine as confirmed virus cases surpass 470,000 amid limited testing and contact tracing. The pandemic has driven the economy into its first recession since the Asian financial crisis and unemployment to a nine-year high.

The country needs about 246 million doses to vaccinate 107 million people ages 18 to 59 years old, Health Minister Terawan Agus Putranto said at the Tuesday meeting. The government will shoulder the cost of nearly 74 million doses. The roll-out would pose unique challenges for Indonesia, which would have to distribute vaccines across more than 17,000 islands.

Novavax, Inc. is set to provide 30 million doses of its vaccine candidate, augmenting Indonesia’s supply of 85 million from China’s Sinovac Biotech Ltd. and 57.6 million of the locally produced, Merah Putih Sadikin told parliament on Tuesday. Indonesia doesn’t have any supply deals with Moderna, Inc., Pfizer, Inc. and BioNTech SE which said their vaccines have above 90% efficacy rates.

While a successful COVID-19 vaccine would be a huge step forward for Indonesia, it would not be a “game-changer, at least in the sense that having a vaccine doesn’t stop the pandemic,” according to Panji Fortuna Hadisoemarto, epidemiologist and virologist at Padjadjaran University.

A vaccine will need to be distributed in stages due to limited availability, which means Indonesia will likely only reach sufficiently large coverage after a few months or even more than a year, Mr. Hadisoemarto said. The speed depends on the vaccine supply and distribution as well as the public’s willingness to get inoculated, he added.

Local clinical trials for the Sinovac vaccine are done and subjects have shown no serious adverse effects as of November 6, according to Penny Lukito, head of the country’s food and drug agency.

The first batch of Sinovac vaccines is slated to arrive at the end of this month. The regulator is ready to authorize it for emergency use once it completes data analysis from the clinical trials, or if U.S. and European regulators do the same, Ms. Lukito said.

The emergency use authorization should take about three weeks to process, Mr. Widodo said.

Indonesia also has rights to access as much as 10% of the total supply in the World Health Organization’s (WHO) pooled Covax clinical trials, which includes Moderna and AstraZeneca Plc’s vaccine candidates, according to Mr. Sadikin.

The government will use a digital platform that will allow it to monitor demographic data, logistics, distribution, procurement and implementation of the vaccination program, Mr. Sadikin said. It will also provide the public with a digital dashboard on the progress of inoculation. — Bloomberg

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!



Armenia-based free educational program TUMO Center for Creative Technologies said it is looking to expand into the Philippines. “We are just at the start...


New research has revealed that funding into new UK businesses still weighs heavily in favour of male-led businesses – who receive 6.2 times more in...


(First of two parts) A week ago, on Thursday, March 23, World Athletics (WA), the international governing body of athletics, announced through its president,...


One study estimates that land-based lithium supplies will be depleted by 2080. And given the high demand now for lithium globally — to use...


Yesterday, Department of Finance (DoF) Secretary Benjamin E. Diokno held a press briefing with the Malacañang press corps and shared his presentations in a...


IN THIS AGE of “disintermediation,” even the barrier to conversations has been rendered passé. Mobile communications allow a caller to access his party without...

You May Also Like


Browsing history makes referring to sites and pages you’ve visited in the past seamless. It’ll help you recall what page you checked out on...


The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...


Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...


Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.